US: TTAB continues to rule on genericness

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

US: TTAB continues to rule on genericness

Sponsored by

katten.png

In In re Hikari Sales USA, Inc., the Trademark Trial and Appeal Board (TTAB) issued a second precedential decision involving genericness, this year, just two days after issuing its first one. In doing so, the TTAB sent a strong message to brand owners hoping to obtain exclusive rights in highly descriptive or otherwise common terms.

Hikari Sales USA (Hikari) filed a trademark application to register the mark ALGAE WAFERS covering fish food, expressly claiming acquired distinctiveness under Section 2(f) based on use since 1991. A USPTO examiner initially refused to register the mark on the ground that the term was merely descriptive, disregarding Hikari's 2(f) claim. In response, Hikari submitted a declaration, advertisements and survey evidence to support its claim of acquired distinctiveness. The examiner maintained the refusal to register, asserting that the mark was generic, and noting that Hikari's additional evidence of acquired distinctiveness showed the term being used descriptively. Hikari appealed the refusal to the TTAB.

The burden of showing that Algae Wafers is a generic name was with the USPTO. In order to succeed, clear and convincing evidence was needed that the primary significance of the term Algae Wafers to the relevant public is a product name (i.e. fish food), and not the product's source (i.e. Hikari). The TTAB used a two-step inquiry to make the determination: "First, what is the genus of goods or services at issue? Second, is the term sought to be registered ... understood by the relevant public primarily to refer to that genus of goods or services?" The undisputed answer to the first question was fish food – the recitation of goods in the application. As for the second question, it had to be decided whether the term Algae Wafers was understood by the public as primarily referring to fish food – including fish food offered in wafer form and containing algae – requiring the TTAB to assess a wide variety of evidence.

The TTAB investigated use of the term Algae Wafers by competitors, use of the term by Hikari, dictionary definitions, media usage, use by people in the trade and the survey conducted by Hikari. Concluding that the term was generic, the TTAB pointed out that (i) a number of competitors used "algae wafers" descriptively; (ii) Hikari's own advertising materials used the term descriptively; (iii) dictionary definitions for "algae" and "wafer" matched Hikari's packaging, which pictured algae in disk (i.e. wafer) form; (iv) third parties used the term algae wafers in books, news stories and on websites; and (v) lawsuits filed by Hikari to stop competitors from using the term, while allegedly successful, could not be properly considered because Hikari never adduced copies of the final orders. Rejecting Hikari's survey evidence, the TTAB pointed out a number of flaws, prior to stating the survey "is not entitled to any weight."

This case serves as a cautionary tale to those considering using a trademark which provides an understandable message to consumers about an attribute of a product or service. Similarly, it serves as a reminder for brand owners and attorneys to consider whether, or to what extent a proposed term is descriptive, when assessing the risks of adopting a term as a trademark.

ash.jpg
jakubovic.jpg

Karen Artz Ash

Jerry Jakubovic


Katten Muchin Rosenman LLP 

575 Madison Avenue

New York, NY 10022-2585

United States

Tel: +1 212 940 8554

Fax: +1 212 940 8671

karen.ash@kattenlaw.com

www.kattenlaw.com


more from across site and SHARED ros bottom lb

More from across our site

An Australian top court decision clarifying honest concurrent use and wins by publishers against AI platforms were also among the top talking points
AIPPI has pulled the plug on its planned 2027 World Congress, and INTA has delayed hosting a meeting there, but the concerns won’t abate
Despite being outspent by a wealthy opponent, a trial attorney at King & Spalding says ‘relentless pursuit of the truth’ helped his team secure a $420m damages award for mobile gaming client
190 drugs face loss of exclusivity between 2026 and 2030, with the list including Bristol Myers Squibb’s blood-thinning drug Eliquis and immunotherapy medication Opdivo
Nokia, represented by a team from Bird & Bird, adjudged to have made fair offer to Asus and Acer in UK SEP dispute
Azhar Sadique and Kane Ridley, who founded the London office in 2023, are now both working in legal tech and AI-related roles, while another UK-based lawyer has also left
Partner Pierre Pérot rejoins the firm he left in 2022 alongside another returning lawyer, associate Camille Abba
Vaping dispute, in which Stobbs and Brandsmiths are the representatives, tested how the UK's Human Rights Act can apply to injunctions restraining unjustified threats
An AI platform being sold for £40m, and lateral hires involving law firms Womble Bond Dickinson and Cadwell Thomas were among the top talking points
With the London Annual Meeting behind us, we look back at some of the lessons learned this week and ahead to what 2027 will bring
Gift this article